University of Trieste-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2021

  1. A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

    Investigational New Drugs, Vol. 39, Núm. 4, pp. 1028-1035